Vaccine therapies for glioma: clinical frontiers and potential breakthrough
Glioma, the most common primary malignant brain tumor, is characterized by high recurrence and mortality rates. Its effective treatment remains a therapeutic challenge in clinical neuro-oncology. Despite over twenty years of exploring new therapies for glioma, progress in improving patient survival...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1613332/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850108540901916672 |
|---|---|
| author | Ying Xing Caixia Liu Yunfeng Feng Shangyu Li Yuping Chen |
| author_facet | Ying Xing Caixia Liu Yunfeng Feng Shangyu Li Yuping Chen |
| author_sort | Ying Xing |
| collection | DOAJ |
| description | Glioma, the most common primary malignant brain tumor, is characterized by high recurrence and mortality rates. Its effective treatment remains a therapeutic challenge in clinical neuro-oncology. Despite over twenty years of exploring new therapies for glioma, progress in improving patient survival outcomes has been limited. Tumor vaccines, as a promising therapeutic approach, may offer hope for glioma treatment. Currently, tumor vaccines targeting glioma include peptide vaccines, dendritic cell vaccines, and nucleic acid vaccines. Neoantigens, due to their high specificity and resistance to central immune tolerance, are ideal targets for tumor vaccines. Although promising results have been resulted in preclinical and clinical for glioma vaccines, there are still challenges impeding vaccine therapy for glioma. Therefore, future glioma vaccine applications must focus on the important roles of epitope spreading and antigen quality in enhancing immune response and therapeutic effectiveness. In this review, we discuss the current glioma vaccine antigen targets and types, introduce recent important clinical studies on glioma vaccines, and propose strategies to address potential barriers to vaccine application. |
| format | Article |
| id | doaj-art-321dd4b4c5f94a9390693d5a601e4d64 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-321dd4b4c5f94a9390693d5a601e4d642025-08-20T02:38:19ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-06-011510.3389/fonc.2025.16133321613332Vaccine therapies for glioma: clinical frontiers and potential breakthroughYing Xing0Caixia Liu1Yunfeng Feng2Shangyu Li3Yuping Chen4Key Laboratory of Clinical Research on Respiratory and Digestive Diseases, Baoding Institute of Pediatrics, Baoding Hospital of Beijing Children’s Hospital, Capital Medical University, Baoding, Hebei, ChinaKey Laboratory of Clinical Research on Respiratory and Digestive Diseases, Baoding Institute of Pediatrics, Baoding Hospital of Beijing Children’s Hospital, Capital Medical University, Baoding, Hebei, ChinaDepartment of Research & Development, Celest Therapeutics (Shanghai) Co., Ltd, Shanghai, ChinaKey Laboratory of Clinical Research on Respiratory and Digestive Diseases, Baoding Institute of Pediatrics, Baoding Hospital of Beijing Children’s Hospital, Capital Medical University, Baoding, Hebei, ChinaKey Laboratory of Clinical Research on Respiratory and Digestive Diseases, Baoding Institute of Pediatrics, Baoding Hospital of Beijing Children’s Hospital, Capital Medical University, Baoding, Hebei, ChinaGlioma, the most common primary malignant brain tumor, is characterized by high recurrence and mortality rates. Its effective treatment remains a therapeutic challenge in clinical neuro-oncology. Despite over twenty years of exploring new therapies for glioma, progress in improving patient survival outcomes has been limited. Tumor vaccines, as a promising therapeutic approach, may offer hope for glioma treatment. Currently, tumor vaccines targeting glioma include peptide vaccines, dendritic cell vaccines, and nucleic acid vaccines. Neoantigens, due to their high specificity and resistance to central immune tolerance, are ideal targets for tumor vaccines. Although promising results have been resulted in preclinical and clinical for glioma vaccines, there are still challenges impeding vaccine therapy for glioma. Therefore, future glioma vaccine applications must focus on the important roles of epitope spreading and antigen quality in enhancing immune response and therapeutic effectiveness. In this review, we discuss the current glioma vaccine antigen targets and types, introduce recent important clinical studies on glioma vaccines, and propose strategies to address potential barriers to vaccine application.https://www.frontiersin.org/articles/10.3389/fonc.2025.1613332/fullgliomavaccineepitope spreadingneoantigenantigen quality |
| spellingShingle | Ying Xing Caixia Liu Yunfeng Feng Shangyu Li Yuping Chen Vaccine therapies for glioma: clinical frontiers and potential breakthrough Frontiers in Oncology glioma vaccine epitope spreading neoantigen antigen quality |
| title | Vaccine therapies for glioma: clinical frontiers and potential breakthrough |
| title_full | Vaccine therapies for glioma: clinical frontiers and potential breakthrough |
| title_fullStr | Vaccine therapies for glioma: clinical frontiers and potential breakthrough |
| title_full_unstemmed | Vaccine therapies for glioma: clinical frontiers and potential breakthrough |
| title_short | Vaccine therapies for glioma: clinical frontiers and potential breakthrough |
| title_sort | vaccine therapies for glioma clinical frontiers and potential breakthrough |
| topic | glioma vaccine epitope spreading neoantigen antigen quality |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1613332/full |
| work_keys_str_mv | AT yingxing vaccinetherapiesforgliomaclinicalfrontiersandpotentialbreakthrough AT caixialiu vaccinetherapiesforgliomaclinicalfrontiersandpotentialbreakthrough AT yunfengfeng vaccinetherapiesforgliomaclinicalfrontiersandpotentialbreakthrough AT shangyuli vaccinetherapiesforgliomaclinicalfrontiersandpotentialbreakthrough AT yupingchen vaccinetherapiesforgliomaclinicalfrontiersandpotentialbreakthrough |